The "Motoric Cognitive Risk" Syndrome in the Canadian Population

Cardiovascular Diseases Clinical Trial

— MCR-CardioV  

Official title:

The "Motoric Cognitive Risk" Syndrome in the Canadian Population: Analysis of Baseline Assessment of the Canadian Longitudinal Study on Aging (CLSA)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03679026
• Other study ID #: CODIM-FLP-16 261
• Status: Active, not recruiting
• Start date: August 22, 2017
• Est. completion date: December 21, 2024

Study information

• Verified date: April 2024
• Source: Jewish General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cognition and locomotion are two human abilities controlled by the brain. Their decline is highly prevalent with aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. Recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that "motoric cognitive risk" (MCR) syndrome, which has been described in cognitively healthy individuals and combines subjective cognitive complaint with objective slow gait speed, is a pre-dementia syndrome. The uniqueness of "motoric cognitive risk" (MCR)syndrome is that it does not rely on a complex evaluation or laboratory investigations. Thus, it is easy to apply in population-based settings. The overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (MCR) syndrome, in the Quebec population using the database of the NuAge study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1461
• Est. completion date: December 21, 2024
• Est. primary completion date: August 21, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 85 Years

Eligibility

Inclusion Criteria:

• Individuals eligible for this study will be participants of the NuAge study

Exclusion Criteria:

• Individuals not eligible for the NuAge study

• dementia

• mobility disability

• no information about cognitive complaint

• no measure of walking speed

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Cognition Disorders
• Cognition Disorders in Old Age
• Dementia

Intervention

Other:
• Summarize of participants' characteristics using means and standard deviations or frequencies and percentages
Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.

Locations

Country	Name	City	State
Canada	Jewish General Hospital	Montréal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Jewish General Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardio-vascular risk factors and diseases assessed using reported health condition	medical history	1 day
Secondary	Cardio-vascular risk factors and diseases assessed using physical examination: BMI	body mass index	1 day
Secondary	Cardio-vascular risk factors and diseases assessed using physical examination: HW ratio	hip-waist ratio	1 day
Secondary	Cardio-vascular risk factors and diseases assessed using physical examination: blood pressure	(value of systolic, diastolic when participants are seated in an upright position in a chair)	1 day
Secondary	Disability and functional limitations	Disability and functional limitations : ADL (activities of daily life)	1 day
Secondary	Disability and functional limitations	Disability and functional limitations : IADL (instrumental activities of daily life)	1 day
Secondary	Disability and functional limitations	History of falls during the past 12 months	12 months
Secondary	Depression	measured by the 10 items of the Center for Epidemiological Studies Short Depression Scale. Participants with a score of 10 or greater are considered as depressed. Scores with more than 2 missing items will be excluded.	1 day
Secondary	Cognitive performance	Prospective Memory Test (PMT)	1 day
Secondary	Cognitive performance	Stroop Neurological Screening Test	1 day
Secondary	Cognitive performance	Controlled Oral Word Association Test (FAS)	1 day
Secondary	Cognitive performance	Choice Reaction Time Test (CRT)	1 day
Secondary	physical and mental health	Number of drugs daily taken	1 day
Secondary	physical and mental health	Self-perception of health and mental health	1 day
Secondary	Physical performance	Muscle strength estimated using the handgrip strength	1 day
Secondary	Physical performance	five-time sit-to-stand test	1 day
Secondary	Physical performance	Physical Activity Scale for the Elderly, scored between 0 and 400, low scores indicate sarcopenia	1 day